Post-ATHENA and beyond

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter). This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial. These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect.

Original languageEnglish (US)
Pages (from-to)55-60
Number of pages6
JournalJournal of Interventional Cardiac Electrophysiology
Volume31
Issue number1
DOIs
StatePublished - Jun 1 2011

Fingerprint

Atrial Flutter
Amiodarone
Atrial Fibrillation
Hospitalization
Cause of Death
Placebos
dronedarone

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

@article{0b14399356eb4d76b6f37920e2d98919,
title = "Post-ATHENA and beyond",
abstract = "Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter). This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial. These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect.",
author = "Gerald Naccarelli",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s10840-011-9550-8",
language = "English (US)",
volume = "31",
pages = "55--60",
journal = "Journal of Interventional Cardiac Electrophysiology",
issn = "1383-875X",
publisher = "Springer Netherlands",
number = "1",

}

Post-ATHENA and beyond. / Naccarelli, Gerald.

In: Journal of Interventional Cardiac Electrophysiology, Vol. 31, No. 1, 01.06.2011, p. 55-60.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Post-ATHENA and beyond

AU - Naccarelli, Gerald

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter). This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial. These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect.

AB - Dronedarone, an amiodarone analog, was developed to be a safer alternative to amiodarone. Dronedarone is useful in suppressing atrial fibrillation/flutter and controlling the ventricular response. Dronedarone reduced cardiovascular hospitalization in the ATHENA trial (A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patiENts with Atrial fibrillation/atrial flutter). This paper reviews the results of ATHENA, including subsequent sub-analyses of the trial. These results raise the hypothesis that many of the benefits noted from this trial may be secondary to more than the antiarrhythmic properties of dronedarone. Future studies will clarify the mechanisms of this beneficial effect.

UR - http://www.scopus.com/inward/record.url?scp=79959572851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959572851&partnerID=8YFLogxK

U2 - 10.1007/s10840-011-9550-8

DO - 10.1007/s10840-011-9550-8

M3 - Review article

C2 - 21336617

AN - SCOPUS:79959572851

VL - 31

SP - 55

EP - 60

JO - Journal of Interventional Cardiac Electrophysiology

JF - Journal of Interventional Cardiac Electrophysiology

SN - 1383-875X

IS - 1

ER -